Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

P. Leif Bergsagel, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Shaji K. Kumar, MD, Sikander Ailawadhi, MD, Angela Dispenzieri, MD, Francis Buadi, MD, Morie A. Gertz, MD, A. Keith Stewart, MD, Craig B. Reeder, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Yi Lin, MD PhD, Asher Alban Chanan-Khan, MD, Marta Chesi, PhD

Blood (2015) 126 (23): 3039.

https://doi.org/10.1182/blood.V126.23.3039.3039

Published: 2015

Journal Articles

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Blood (2015) 126 (23): 703.

https://doi.org/10.1182/blood.V126.23.703.703

Published: 2015

Journal Articles

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Aneel Paulus, MDMS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, MPhil, Hassan Yousaf, Davitte Cogen, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, James M. Foran, MD, Candido E. Rivera, MD, Taimur Sher, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 2754.

https://doi.org/10.1182/blood.V126.23.2754.2754

Published: 2015

Journal Articles

Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma

Abhisek Swaika, MBBS, Vivek Roy, MD, Zhuo Li, M.S, Neha Sood, MD, Kristina Laumann, Amanda Shreders, MD, Joseph Mikhael, MD, Shaji Kumar, MD, Asher Alban Chanan-Khan, MD, Martha Q. Lacy, MD, Sikander Ailawadhi, MD

Blood (2015) 126 (23): 1839.

https://doi.org/10.1182/blood.V126.23.1839.1839

Published: 2015

Journal Articles

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Pooja Advani, MBBS, Thomas E. Witzig, MD, George J Weiner, MD, Sikander Ailawadhi, MD, Joachim Gullbo, MD PhD, Stig Linder, PhD, Geraldo Otero-Colon, Kasyapa S. Chitta, PhD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1557.

https://doi.org/10.1182/blood.V126.23.1557.1557

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1279.

https://doi.org/10.1182/blood.V126.23.1279.1279

Published: 2015

Journal Articles

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Sharoon Akhtar, MPhil, Aneel Paulus, MDMS, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Vivek Roy, MD, Taimur Sher, MD, James M. Foran, MD, Candido E. Rivera, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 4839.

https://doi.org/10.1182/blood.V126.23.4839.4839

Published: 2015

Journal Articles

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

Jennifer A Crozier, MD, Taimur Sher, MD, Dongyun Yang, PhD, Abhisek Swaika, MBBS, James M. Foran, MD, Han W Tun, MD, Gerardo Colon-Otero, MD, Asher Alban Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2014) 124 (21): 2597.

https://doi.org/10.1182/blood.V124.21.2597.2597

Published: 2014

Journal Articles

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Paul Richardson, MD, Craig C. Hofmeister, MD, Todd M. Zimmerman, MD, Asher Alban Chanan-Khan, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Sandra Wear, Alison L. Hannah, MD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2770.

https://doi.org/10.1182/blood.V112.11.2770.2770

Published: 2008

Journal Articles

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Umeer Ashraf, MD, Ritika Mahajan, MBBS, Theresa Hahn, PhD, Shannon L Smiley, MD, Philip L. McCarthy, MD, Zale P. Bernstein, MD, Asher Alban Chanan-Khan, MD, Minoo Battiwala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 1138.

https://doi.org/10.1182/blood.V112.11.1138.1138

Published: 2008

Journal Articles

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Toshihiko Ishii, Asher Alban Chanan-Khan, MD, Jazur Jafferjee, MD, Noreen Ersing, Takeshi Takahashi, PhD, Masato Mizutani, PhD, Yukimasa Shiotsu, PhD, Nobuo Hanai, PhD

Blood (2008) 112 (11): 1718.

https://doi.org/10.1182/blood.V112.11.1718.1718

Published: 2008

Journal Articles

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Asher Alban Chanan-Khan, MD, Nikhil C. Munshi, MD, Mohamad A. Hussein, M.D., Laurence Elias, MD, Fabio Benedetti, M.D., Jennifer Smith, Ph.D., Soo-Peang Khor, Ph.D., Carol A. Huff, MD

Blood (2008) 112 (11): 3688.

https://doi.org/10.1182/blood.V112.11.3688.3688

Published: 2008

Journal Articles

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Asher Alban Chanan-Khan, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C Anderson, MD, Dawn DePaolo, Kelvin P. Lee, MD, Kena Miller, RN, MSN, FNP, Robin Guild, Sybil Zildjian, Albert Qin

Blood (2008) 112 (11): 3689.

https://doi.org/10.1182/blood.V112.11.3689.3689

Published: 2008

Journal Articles

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Clemens M Wendtner, MD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, MD, PhD, Olga Frankfurt, MD, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Lutz Uharek, Richard R Furman, MD, Marco Gobbi, John G. Gribben, MD, DSc, Eva K. Kimby, MD, PhD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD, Elyane Lombardy, Sheetal Shah, Laure A Moutouh-de Parseval, Asher Alban Chanan-Khan, MD, Robert D. Knight, MD

Blood (2008) 112 (11): 2104.

https://doi.org/10.1182/blood.V112.11.2104.2104

Published: 2008

Journal Articles

Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment.

Jayakumar R Nair, PhD, Louise M Carlson, PhD, Noreen Ersing, MS, Asher Alban Chanan-Khan, MD, Kelvin P. Lee, MD

Blood (2008) 112 (11): 1664.

https://doi.org/10.1182/blood.V112.11.1664.1664

Published: 2008

Journal Articles

Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens.

Sikander Ailawadhi, MD, Terry L. Mashtare, PhD, Marie V. Coignet, Dawn M. Depaolo, Kena C. Miller, MSN NP, Gregory Wilding, PhD, Asher Alban Chanan-Khan, MD

Blood (2007) 110 (11): 1477.

https://doi.org/10.1182/blood.V110.11.1477.1477

Published: 2007

Journal Articles

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

Peter Maslak, MD, James Caravelli, MD, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 2834.

https://doi.org/10.1182/blood.V108.11.2834.2834

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Alban Chanan-Khan, MD, Zhinuan Yu, PhD, Donna Weber, MD, Christine Chen, MD, Ruben Niesvizky, MD, Andrew Spencer, MD, Michel Attal, MD, Andrew Belch, MD, Miles Prince, MD, Marta Olesnyckyj, Robert Knight, MD, Jerome Zeldis, MD, Meletius Dimopoulos, MD

Blood (2006) 108 (11): 3554.

https://doi.org/10.1182/blood.V108.11.3554.3554

Published: 2006

Journal Articles

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher Alban Chanan-Khan, MD, Sundar Jagannath, MD, Robert L. Schlossman, MD, Robert J. Fram, MD, Richard M. Falzone, Mary F. Ruberti, Samantha K. Welch, Dawn DePaolo, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3574.

https://doi.org/10.1182/blood.V108.11.3574.3574

Published: 2006

NARROW

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment.

Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens.

“Complete” Remission in Chronic Lymphocytic Leukemia (CLL) Is Strongly Affected by the Use of CT Scanning: Results from a Prospective Randomized Trial of Fludarabine Plus Cyclophosphamide (Flu/Cy) with or without Genasense (Oblimersen) in Patients with Relapsed or Refractory Disease.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only